| Revenue growth | 14.1% YoY in Q1 FY27 |
|---|---|
| Margins | Gross margin expanded to 46.5%; EBITDA margin slightly down |
| Demand visibility | Strong; 200+ product registrations in pipeline |
| Management confidence | High; citing improved business mix and strategic priorities |
Growth
Q1 FY27 revenue grew 14% to ₹80.68 Cr; PAT surged 347% to ₹1.29 Cr; Gross margins expanded 241 bps.
Outlook
Targeting top-2 positions in frontier markets; expansion into Ecuador and Chile; scaling new Hyderabad facility for better margins.
Risks
Old FY26 results showed 7.7% revenue decline; transition from asset-light to asset-heavy manufacturing carries execution risks.
Investor Presentation filed with NSE, NSE: BALAXI. Summary written with AI assistance from the document.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.82
- Market cap
- ₹126.0 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 52.0×Sector 50.4×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.3 Cr, Up 333.3% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.3 Cr · +333.3% YoY
Balaxi Pharmaceuticals Earnings Call: Key Takeaways
Balaxi's FY26 was a transformational year focused on backward integration. Despite a 7.7% revenue decline to ₹270.17 Cr due to working capital issues in Angola, gross margins improved to 44.2%.
Balaxi Pharmaceuticals Q4 FY26 Results: Net Profit ₹0.6 Cr, Down 93.0% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹70.7 Cr (-7.3% YoY) and net profit of ₹0.6 Cr (-93.0% YoY) for Q4 FY26.
- Key figure
- Net profit ₹0.6 Cr · -93.0% YoY